secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001171843-25-001352
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025
-------------------------------------------------------------------

- Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.
- Cash & investments $56.9M at Dec 31, 2024; $105M private placement closed Feb 2025 extends runway into H2 2026.
- Lead CAM-E candidate ALG-000184 Phase 2 expected to start mid-2025; 96-week data to be presented in 2025.
- THR-β agonist ALG-055009 for MASH showed up to 46.2% placebo-adjusted median relative liver fat reduction at Week 12.
- Lesley Ann Calhoun promoted to EVP, COO and CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325001352/0001171843-25-001352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325001352/f8k_031025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer